Lipocine's LPCN 1154 Phase 3 data selected for oral presentation at 2026 ASCP meeting

Lipocine announced that Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for postpartum depression, was accepted for oral and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting in May 2026. The presentation will showcase results from the company's placebo-controlled trial evaluating the drug's efficacy and tolerability profile.